

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: A61K 45/06

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: SCHERING AKTIENGESELLSCHAFT
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: SIEMEISTER, Gerhard [DE/DE]; Reimer-
swalder Steig 26, 13503 Berlin (DE). HABEREY, Mar-
tin [DE/DE]; Steinstr. 1, 12169 Berlin (DE). THIER-
AUCH, Karl-Heinz [DE/DE]; Hochwildpfad 45, 14169
Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

BEST AVAILABLE COPY



WO 01/97850 A2

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE
RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular
Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of
Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during
10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and
25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was
30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendotherial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

- 10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
- 15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
- 20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
- 25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

- Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
- 30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothellum to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.


30 A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhUMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579. Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

- 10 Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I




in which

r has the meaning of 0 to 2,

n has the meaning of 0 to 2;


R₃ und R₄ a) each independently from each other have the meaning of lower alkyl,

b) together form a bridge of general partial formula II,



wherein the binding is via the two terminal C- atoms, and m has the meaning of 0 to 4; or

c) together form a bridge of partial formula III



wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or
lower alkyl,
X has the meaning of imino, oxa or thia;
5 Y has the meaning of hydrogen, unsubstituted or substituted
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
Z has the meaning of amino, mono- or disubstituted amino,
halogen, alkyl, substituted alkyl, hydroxy, etherificated or
esterificated hydroxy, nitro, cyano, carboxy, esterificated
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
15 if more than one rest Z is present ($m \geq 2$), the substituents Z are
equal or different from each other, and wherein the bonds
marked with an arrow are single or double bonds; or an N-
oxide of said compound, wherein one ore more N-atoms carry
an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive
pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenese,
respectively, which results in a prevention of tumor growth and tumor spread, are
for example

anthranil acid derivatives of general formula IV

30



in which

A


has the meaning of group $=NR^2$,

W


has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q$, branched or unbranched C_{1-6} -Alkyl or is the group



or A, Z and R^1 together form the group



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

5

X

Y

p

R¹

15

R²

20

R³

25

R⁴, R⁵, R⁶ and R⁷

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/ or R_a and/ or R_b together with R_c and or R_d or R_e together with R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

has the meaning of group =NR⁹ or =N-,has the meaning of group -(CH₂)_p,

has the meaning of integer 1-4,


has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of fur halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,

independently from each other have the meaning of hydrogen, halogen or C₁₋₆-alkoxy, C₁₋₆-alkyl or

C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group




5

R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.

These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V



V,


15

in which



R¹

has the meaning of group





20




14



in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,




in which R^8 is $-\text{CH}_3$, fluoro, chloro or $-\text{CF}_3$

in which R^4 is fluoro, chloro, bromo, $-\text{CF}_3$, $-\text{N}=\text{C}$, $-\text{CH}_3$, $-\text{OCF}_3$ or $-\text{CH}_2\text{OH}$

in which R^6 is $-\text{CH}_3$ or chloro

R^2

has the meaning of pyridyl or the group



and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocol. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites
5 formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch,
10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as
15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients
25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
- 5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
- 10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
- 25 tyrosine kinases Tie1 and Tie2.

- Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
- 30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, maligneous nephrosclerosis, thrombic microangiopatic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, artherosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

15

20

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in
5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of
10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its
15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a
5 inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of
10 intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv)

specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing

10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx.

200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of

treatment are described in Table 3. Animals were sacrificed for ethical reasons

15 when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.
 15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

- Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
- 5 separate modes of intervention in inhibition of tumor growth.

- Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate
- 10 (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
- 15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days.

10

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

15

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

mock, con.	=	treatment group 1
mock+VEGF-A	=	treatment group 2
sTIE2-cl13	=	treatment group 3
sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I
10 which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I
which modulates the biological function of one or several of the VEGF/VEGF
receptor systems or of one or several of the Angiopoietin/ Tie receptor systems
and comprising one or several agents as compound II which are targeted to
the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I
which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie
receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound
I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.

10

8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.

10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of

20

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,

25

- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

30

- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.


12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I

41



I,

in which

5

r

has the meaning of 0 to 2,


n

has the meaning of 0 to 2;

R₃ und R₄

10

- a) each independently from each other have the meaning of lower alkyl,
 b) together form a bridge of general partial formula II,



II,

15


wherein the binding is via the two terminal C- atoms,
 and

m

has the meaning of 0 to 4; or

- c) together form a bridge of partial formula III

20



has

wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

5

G

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

10

A, B, D, E and T

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15

Q

has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2

independently from each other have the meaning of H or lower alkyl,

X

has the meaning of imino, oxa or thia;

20

Y

has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z

has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single


25

30

or double bonds; or an N-oxide of said compound,
wherein one or more N-atoms carry an oxygen atom,
or a salt thereof,

and/or a compound of general formula IV

5



in which

A

has the meaning of group $=NR^2$,

10


W

has the meaning of oxygen, sulfur, two hydrogen atoms
or the group $=NR^8$,

Z


has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$,
 $(CH_2)_q$, branched or unbranched C_{1-6} -Alkyl or is the
group

15



or A, Z and R^1 together form the group

20



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/or R_a and/or R_b together with R_c and/or R_d or R_c together with R_e and/or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

X

has the meaning of group =NR⁹ or =N-,

Y

has the meaning of group -(CH₂)_p,

p

has the meaning of integer 1-4,

R¹

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

R²


has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

R³

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R^4, R^5, R^6 and R^7


substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or C_{1-6} -alkoxy, C_{1-6} -alkyl or C_{1-6} -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R^5 and R^6 together form the group



R^8, R^9 and R^{10}

independently from each other have the meaning of hydrogen or C_{1-6} -alkyl, as well as their isomers and salts,

and/ or a compound of general formula V




V,

in which


R^1 has the meaning of group

46




in which R^5 is chloro, bromo or the group $-OCH_3$,

5



in which R^7 is $-CH_3$ or chloro,



in which R^8 is $-CH_3$, fluoro,
chloro or $-CF_3$


in which R^4 is fluoro,
chloro, bromo, $-CF_3$,
 $-N=C$, $-CH_3$, $-OCF_3$ or
 $-CH_2OH$

in which R^6 is
 $-CH_3$ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their
isomers and salts.

15

16. Pharmaceutical compositions according to claim 15 which comprise as
compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-
yl]ammonium hydrogen succinate

20

17. Pharmaceutical compositions according to claims 1-16 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium
hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF
conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-
phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-
tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not
identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

5 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

10 20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPMLXX00-P

15

<140>

<141>

<160> 59

20

<210> 1

<211> 1835

<212> DNA

<213> Human

25

<400> 1

30

```

ttttacagtt ttctttttct tcagagttaa ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaac gccaaaaaac cataatggtg ccacagggat ggagcaggga agggcatctc 300
taacgtgtcc tctagtctat ctctgctaaa cagaaccac gttacacatg ataactagag 360
agcactgtgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctacagcggt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccacaaacgca acctaaccac agcaaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagegatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatectta gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcgggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc agggggcgaca 1080
tccgccaaag tcctccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccggttc 1200
ctccacgaac gggtagcggc ttocatgaga aaggatattt ggcaatttta tattccacag 1260
tcaggtgggt ctgcgatagc tcatttaatg ttaaaccgca tcaggggcct ctctcccgt 1320
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat ccgagtcctg tctggctgct tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgacccttc caacaagcat cgcagggcac 1500
gttctcggg ggtacagacc gtgggtccac attogctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggtctcttc tgctgggtgct 1620
cttgagcggg cgggtagttc tgctgcagag acaaagcatc tccccttccc ttccgggctg 1680
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggaact gccatccaag 1800
gagacgaacc acgcccggg gtgcggaagc ggcct

```

60

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagaccc ctggggcctg tgctaccag 60
acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
tcaacttact tctgtggcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180
agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
tgccccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480
aagaaaatct ttagcaatta gatgggagag aagggaaata gtacttgaaa tgtaggccct 540
cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3
<211> 516
<212> DNA
<213> Human

20 <400> 3

tagagatgtt ggttgatgac ccccgggac tggagcagat gaatgaagag tctctggaag 60
tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgcgg aacctgaatg 120
gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
25 ttgttaagct tctgtggccag agtactgatt ctctccaca gactatatgt cggaaccaa 240
agacctccac tgatcgacac agcttgagcc tcatgacat cagactttac cagaaagact 300
tcttgccat tgcaagctg tgcaggaca ctgctcagag ttacacctt ggatgtggcc 360
atgaactgga tgaggaaagg ctctattgca acagttgctt ggcccagcag tgcataca 420
30 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480
atgaagttcc agagtgtgt gtgtaaagtc cgtctg

<210> 4
<211> 1099
<212> DNA
35 <213> Human

<400> 4

cccacaacac aggggcccctg aaacacgcca gcctctctc tgtggtcagc ttggcccagt 60
40 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
gggtgctgctc ttggccttgc cgtgccctca tccccggct gaggcagcga cacagcaggt 240
gcaccaactc cagcaggtta agcaccagg agatgagtc aaccaccaac atgaagatga 300
tgaagatggc cttctccgtg gggcgagaga caaagcagtc cagcaggtag gggcaggtg 360
45 ctcgctggca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420
ggaagcctgc ctctagcaca ctcttgaga gcacactggc gacatagggt cccatcagtg 480
ctccgcggat ggcagggcga ccactctctg ccaccgagat cttggccatc tgacgctcta 540
cgcccgccag cgcccgtctc acctgtgggt ccttggccg cagtgcocgc agctccccct 600
cctctgccc cagccgtctc tctcgccgag acaggtaaat gacatggccc aggtagacca 660
50 ggggtgggtg gctgacgaag aggaactgca gcaccagta gcggatgtgg gagatgggga 720
aggcctggtc atagcagacg ttggtgcagc ctgggtgggc cgtgttacac tcgaaatctg 780
actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
agagcaccgt cagccagatc ttaccacca cggtcgagtg ctctggacc tgggtccaga 900
acttctccac gaagcccag tcacccatgg ctccggggc tccgtcgga aggagacaga 960
55 gcacgtcagt gtgtcagcat ggcactctc tctgtcgccc agcaacaagc ctgcagggag 1020
gtctgccacg cccgttctac cgcctgcctg ccggggcgcc caggtggagg tggggacgat 1080
ggccggagtg acgcccgcg

<210> 5
60 <211> 1015
<212> DNA
<213> Human

<400> 5
65

gaggataggg agcctggggg caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

	aaaaagtgct	ttttgaaaat	gttgaggttg	aaatgatggg	aaccaacatt	ctttggattt	120
	agtggggagc	ataatagcaa	acacccctt	ggttcgcaca	tgtacaggaa	tgggacccag	180
	ttggggcaca	gccatggact	tccccgccct	ggaatgtgtg	gtgcaaagtg	gggcccagggc	240
	ccagacccaa	gaggagaggg	tgggtccgag	acaccccggy	atgtcagcat	ccccgacct	300
5	gcctttctggc	ggcacctccc	gggtgctgtg	ttgagtcagc	aggcatgggg	tgagagcctg	360
	gtatatgctg	ggaacagggt	gcaggggcca	agcgttcctc	cttcagcctt	gacttggggc	420
	atgcaccccc	tctcccccaa	acacaaacaa	gcacttctcc	agtatggtgc	caggacaggt	480
	gtcccttcag	tcctctggtt	atgacctcaa	gtcctacttg	ggccctgcag	cccagcctgt	540
	gttgtaacct	ctgcgtctct	aagaccacac	ctggaagatt	cttcttccct	ttgaaggaga	600
10	atcatcattg	ttgctttatc	acttctaaga	cattttgtac	ggcacggaca	agttaaacag	660
	aatgtgcttc	cctccctggg	gtctcacacg	ctcccacgag	aatgccacag	gggcccgtgca	720
	ctgggcaggg	ttctctgtag	aaccccaggg	gcttcggccc	agaccacagc	gtcttgccct	780
	gagcctagag	cagggagtc	cgaacttctg	cattcacaga	ccacctccac	aattgttata	840
	accaaaggcc	tcctgttctg	ttatttcaat	taaatcaaca	tgctattttg	ttttcactca	900
15	cttctgactt	tagcctcggt	ctgagccgtg	tatccatgca	gtcatgttca	cgtgctagtt	960
	acgtttttct	tcttacacat	gaaaataaat	gcataagtgt	tagaagaaaa	aaaaa	
	<210> 6						
	<211> 2313						
20	<212> DNA						
	<213> Human						
	<400> 6						
25	ccagagcagg	cctggtggtg	agcagggagc	gtgcaccgga	cggcgggatc	gagcaaatgg	60
	gtctggccat	ggagcacgga	gggtcctacg	ctcgggcggg	gggcagctct	cggggctgct	120
	ggtattacct	gogctacttc	ttcctcttcg	tctccctcat	ccaattcctc	atcatcctgg	180
	ggctcgtgct	cttcatggtc	tatggcaacg	tgcacgtgag	cacagagtcc	aacctgcagg	240
	ccaccgagcg	ccgagccgag	ggcctataca	gtcagctcct	agggtcacg	gcctcccagt	300
30	ccaacttgac	caaggagctc	aacttcacca	cccgcgccaa	ggatgccatc	atgcagatgt	360
	ggctgaatgc	tcgcccgcac	ctggaccgca	tcaatgccag	cttccgccag	tgccagggtg	420
	accgggtcat	ctacacgaac	aatcagaggt	acatggctgc	catcatcttg	agtgagaagc	480
	aatgcagaga	tcaattcaag	gacatgaaca	agagctgcga	tgcccttgctc	ttcatgctga	540
	atcagaaggt	gaagacgctg	gaggtggaga	tagccaagga	gaagaccatt	tgactaagg	600
35	ataaggaaag	cgtgctgctg	aacaaacgcy	tggcgaggga	acagctgggt	gaatgcgtga	660
	aaacccggga	gctgcagcac	caagagcgcc	actggccaag	gagcaactgc	aaaagggtgca	720
	agccctctgc	ctgcccctgg	acaaggacaa	gtttgagatg	gaccttcgta	acctgtggag	780
	ggactccatt	atcccacgca	gcctggacaa	cctgggttac	aacctctacc	atcccctggg	840
	ctcggaattg	gcctccatcc	gcagagcctg	cgaccacatg	cccagcctca	tgagctccaa	900
40	ggtggaggag	ctggcccggg	gcctccgggc	ggatategaa	cgcgtggccc	gcgagaactc	960
	agactcccaa	cgccagaagc	tggaagccca	cgaggccctg	cgggccagtc	aggaggcgaa	1020
	acagaaggtg	gagaaggagg	ctcaggcccg	ggaggccaag	ctccaagctg	aatgctcccg	1080
	gcagaccag	ctagcgtctg	aggagaaggc	ggtgctgcgg	aaggaacgag	acaacctggc	1140
	caaggagctg	gaagagaaga	agagggaggc	ggagcagctc	aggatggagc	tgcccatcag	1200
45	aaactcagcc	ctggacacct	gcatcaagac	caagtgcgag	ccgatgatgc	cagtgtcaag	1260
	gccccatggg	cctgtcccca	accccagcc	catcgacca	gctagcctgg	aggagttcaa	1320
	gaggaaagtc	ctggagtcct	agaggccccc	tgcaggcatc	cctgtagccc	catccagtgg	1380
	ctgaggaggg	tccaggcctg	aggaccaagg	gatggcccga	ctcggcggtt	tgccggaggat	1440
	gcagggatat	gctcacagcg	cccgcacaaa	ccccctcccg	ccgcccccaa	ccaccagggg	1500
50	gcaccatcag	acaactccct	gcattgcaaac	ccctagtacc	ctctcacacc	cgcaccgcgc	1560
	cctcacgcat	cctcacccag	agcacacggc	cgcggagatg	acgtcacgca	agcaacggcg	1620
	ctgacgtcac	atatcaccgt	ggtgatggcg	tcacgtggcc	atgtagacgt	cacgaagaga	1680
	tatagcgatg	gcgtcgtgca	gatgcagcac	gtcgcacaca	gacatgggga	acttggcatg	1740
	acgtcacacc	gagatgcagc	aacgacgtca	cgggccatgt	cgacgtcaca	catattaatg	1800
55	tcacacagac	cgggcgatgg	catcacacag	acggtgatga	tgteacacac	agacacagtg	1860
	acaacacaca	ccatgacaac	gacacctata	gatattggcac	caacatcaca	tgacgcgatg	1920
	ccctttcaca	cacactttct	acccaattct	cacctagtgt	cacgttcccc	cgaccctggc	1980
	acacgggcca	aggtacccac	aggatcccat	cccctcccgc	acagccctgg	gccccagcac	2040
	ctccctcct	ccagcttcc	ggcctcccag	ccacttctct	accccagtg	cctggaccgc	2100
60	gaggtgagaa	caggaagcca	ttcacctccg	ctccttgagc	gtgagtggtt	ccaggacccc	2160
	ctcggggccc	tgagccgggg	gtgaggttca	cctgttgctg	ggaggggagc	cactccttct	2220
	cccccaactc	ccagccctgc	ctgtggcccg	ttgaaatgtt	ggtggcactt	aataaatatt	2280
	agtaaatcct	taaaaaaaaa	aaaaaaaaaa	aaa			
65	<210> 7						
	<211> 389						

<212> DNA
<213> Human

<400> 7

5

10

gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgat atattggtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc

<210> 8
<211> 157
<212> DNA
<213> Human

15

<400> 8

20

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

25

<210> 9
<211> 561
<212> DNA
<213> Human

30

<400> 9

35

40

aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggcctcagcc agcagagaaa gaattctgaa tttcccttgc 120
tgaactgaac tattctgtta catatgggtg acaaatctgt gtgttatttc ttttctacct 180
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgatc 480
ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgcccacat ttctaggaaa a

45

<210> 10
<211> 1508
<212> DNA
<213> Human

<400> 10

50

55

60

65

cacaaacacg agagactcca cggctctgcct gagcaccgcc agcctcctag gctccagcac 60
tcgcaggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcactct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaatct 240
gagctcaagc caggtgagct taagccactg agcaaggaa atttgggctt gcacgcctac 300
aggtgtgagg actgtggcaa gtgcaaatgt aaggagtgca cctaccacaa gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
tgtgtctgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540
ggtgtcatgt cctctttttt gccttgttta tgggtgtacc ttccagccaa ggggtgcctt 600
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc cccctagga actttgaaaa accaactag 720
catcattaat caggaaatatt acagtaatga ggattttttc tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgg gatagctctt 840
gctgttttgc gtgaaatgct tttgtccat gtgccgtttt aactgatatg cttgttagaa 900
ctcagctaat ggagctcaaa gtatgagata cagaacttgg tgacccatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaag tttttgtttg tgaatagtac ttgcaaaact 1020

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55
 60
 65

tgtaaattag	cagatgactt	ttttccattg	ttttctccag	agagaatgtg	ctatatTTTT	1080
gtatatacaa	taatatTTTg	aactgtgaaa	aacaagtgg	gccatactac	atggcacaga	1140
cacaaaatat	tatactaata	tgTTgtacat	tcggaagaat	gtgaatcaat	cagtatgttt	1200
ttagattgta	ttttgcctta	cagaaagcct	ttattgtaag	actctgattt	ccctttggac	1260
ttcatgtata	ttgtacagtt	acagtaaaat	tcaaccttta	ttttctaatt	ttttcaacat	1320
attgtttagt	gtaaagaata	tttatttgaa	gttttattat	tttataaaaa	agaatattta	1380
ttttaagagg	catcttacia	atitttgccc	ttttatgagg	atgtgatagt	tgctgcaa	1440
gaggggttac	agatgcatat	gtccaatata	aaatagaaaa	tatattaacg	tttgaaatta	1500
aaaaaaaa						

<210> 11
 <211> 389
 <212> DNA
 <213> Human

<400> 11

gggcaggtga	tcagggcaca	catttcccgt	ccattgagac	agtagcattc	ccggcaccca	60
tcgtgccagc	tctctcatt	tttatgatga	tgaccatcca	cggtagagac	agtgcccgac	120
aggatgggtg	gcccagctga	agcacaggcc	gctctgcact	tgagataag	acagccgtga	180
ctgtcctgtc	ggaaacccaa	ggggcagatc	ttactgcctg	agagctctgg	acatttctta	240
cagcgacaga	tgccacagcc	gtgcttattc	ttcagcaatc	caagtggaca	atacttgtca	300
cagattatgg	gtctgcactt	cttgggcctt	gggcggcact	cacagatctc	acagttttgg	360
acctcggccg	cgaccacgct	gggtaccga				

<210> 12
 <211> 981
 <212> DNA
 <213> Human

<400> 12

tttttttttt	ttggattgca	aaaatttatt	aaaattggag	acactgtttt	aattcttctg	60
tgccatgaga	ctccatcagg	cagtctacaa	agaccactgg	gaggctgagg	atcacttgag	120
cccagaagtt	tgaggctgta	gtaagcttca	aaggccactg	cactctagct	tgggtgagge	180
aagacccttt	caagcagtaa	gctgcattgt	tgcttggtgt	ggcattataa	aacctagtt	240
taggataaca	acatatattt	cagggcacaa	tacaaatgtg	tgatgcttgt	tagtagagta	300
acctcagaat	caaaatggaa	cggtttttaca	gtgatcatat	tatatattcat	ttggcagaat	360
cattacatca	ttgggttacac	tgaaaatcat	cacatgtacc	aaaagctgac	tcacctagtt	420
taggataaca	ggctctgctg	tttgaagatg	aaaaataata	cccattttaa	atttgcccta	480
ctcaatttct	ttctcagtc	catttttaact	tttaaacagc	taatcactcc	catctacaga	540
ttaaggtgta	tatgccacca	aaaccttttg	ccaccttaaa	aatttccttc	aaagtttaaa	600
ctaattgcctg	catttcttca	atcatgaatt	ctgagtcctt	tgcttcttta	aaacttgctc	660
cacacagtg	agtcaagccg	actctccata	cccaagcaag	tcattccatgg	ataaaaaagt	720
taccaggagc	agaaccatta	agctgggtcca	ggcaagttgg	actccaccat	ttcaacttcc	780
agctttctgt	ctaattgcctg	tgtgccaatg	gcttgagtta	ggcttgctct	ttaggacttc	840
agtagctatt	ctcatccttc	cttggggaca	caactgtcca	taaggtgcta	tccagagcca	900
cactgcattc	gcacccagca	ccatacctca	caggagtcga	ctccacagag	ccgcctgtat	960
ataagagttc	ttttgatgac	g				

<210> 13
 <211> 401
 <212> DNA
 <213> Human

<400> 13

ataactacag	cttcagcaga	caactaaaga	gactgcatta	agggtatttc	tctggctata	60
aagagagccc	ggccgcagag	catgtgactg	ctgggacctc	tgggataggc	aacactgccc	120
tctctcccc	agagcgaccc	cccgggcagg	tcggggccca	aggaatgacc	cagcaactgc	180
tccctaccca	gcacactctc	ttactgccta	ctgcaatta	tgctgtgaag	atgactgggt	240
gtggctcatca	cgattcgagag	aaatcaagat	ctatgacat	tttaggcaaa	gagagaaact	300
tggagaattg	ctgaggacta	ctgaaccttg	ttttgctttt	ttaaaaaata	ctaaatcctc	360
acttcagcat	atttagttgt	cattaaaatt	aagctgatat	t		

<210> 14

<211> 1002
 <212> DNA
 <213> Human

5 <400> 14

```

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
tttgaataatg ttaaatacaa gtccctattct ctttgtccag ctgggttttag ctagaggttag 180
10 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
gaagtaataa tctggggccc atcgaccccc cactaagtac tttgtcacca tgtgtatct 300
taaaagtcac ttttctactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420
tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
15 tactgaaaac aatggtgcca tatgctccaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
attaatacag ctcaaatgga gtagtaacca agcttttctg cccaggaagt aacaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatc 720
attcaataaa cattagccaa gctaattgtc caagccactg tgccagggtat taacaatata 780
20 acaacaataa aagacacagt ccttcctctc aagggtgttca gtctagtagg gaagatgatt 840
attcattaaa atttttgggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900
gcctatgttc tcagatatc tgggttaggtc aggagtggga acccaaaatc aattctttta 960
acaaacacta aaggtgatc taacacaggc ggtgtgagga cc

```

25 <210> 15
 <211> 280
 <212> DNA
 <213> Human

30 <400> 15

```

cgagggtgggc caccctgtgc tgggtctgaga tttttaaatg aggattacat taccctattt 60
ataatattcc tattctaatc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
35 aactgtatta tgactctcaa tatttaaaca ttttaaaaaa tgtttagtgtt tgttaagcac 240
caatcttaac tatttcacct gcccgggcgg ccgctcgagg

```

40 <210> 16
 <211> 2041
 <212> DNA
 <213> Human

<400> 16

```

45 cccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60
atagaggtta gcatttttta ggtaaaaaata tgggtgcccc tacagggatc atgcaacttc 120
cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
aattttgtta ttgccttctt tagagacttt ataattctta gttgattttc aaggacttga 300
50 atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
ttaccttag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480
caggtaacata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaatttttaag aggttagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
55 ataaaaacaa gcaactgagt ttttctcttg aagtataagg gtctaataaa aaataaaaga 660
tagatatattg ttatagctcg acattttaac agtcatagta ttagacgttt cgtgaccagt 720
gcatttttga ctctctcagg atcaaaaatac gagtctgcca actgtattaa atcctcctcc 780
acccctccca ccagttgggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900
60 ttctgtataa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactggt tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataagc tgtgtcttct ggaaacctgc tcgtaatttt 1080
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaaaataaaa acccattctt 1140
ttgacatttc cttattttcc aaatcctggt caaaaaactgc actgggacta tctctccta 1200
65 gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctggtggtac atctgatatg 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgccactt tcagaggata 1320

```

	taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caattttgtg	caggaagctt	1380
	catcagtgccc	tgaaggcttt	aatttttttag	caagggttctc	actaagatca	gtgaagtcaa	1440
	catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500
5	cctaaaccag	tggccagtg	tacattgtct	aaaattttcc	ttctcacatg	atacttctga	1560
	tcatatgaaa	atctcaggag	agtaagaata	aggtattcag	gttcctccgt	gatttgata	1620
	gttttctcag	cattttgcag	agaggcacag	ttttcacaat	aatattgggt	atcaccagta	1680
	agaatctctg	gagcccaaaa	aataatttag	taagtcagtt	actgaagggtg	tggtttcacc	1740
	tcccggtttc	tgaggtagat	ctttattaac	agaatcttg	ttagattcgt	tagggacaga	1800
	agtgttttca	gaacagtaaa	actcattagg	aggactgcct	atggtttttt	cattcacaag	1860
10	tgagtcacag	atgaaggcag	ctgttgttgg	attataaact	actggctctt	ctgaaggacc	1920
	gggtacacag	gcttgcatga	gaccaccatc	ttgtatactg	ggtgatgatg	ctggatcttg	1980
	gacagacatg	ttttccaaag	aagaggaagc	acaaaacgca	agcgaaagat	ctgtaaaggc	2040
	t						
15	<210> 17						
	<211> 235						
	<212> DNA						
	<213> Human						
20	<400> 17						
	cgccccgggc	aggtgtcagg	ggttccaaac	cagcctgggg	aaacacagcg	tagacccttc	60
	acctctacaa	ataaaaaatt	aaaaaattag	ccaggtgtgg	cagcgaacaa	ctgtagtctc	120
	agatactcag	gagactgagc	tggaaaggat	cacttgagcc	caagaagttc	aaggttacag	180
25	tgggccacga	tcatgtcatt	acactccagc	ttgggtgaca	aatgagact	gtcta	
	<210> 18						
	<211> 2732						
	<212> DNA						
30	<213> Human						
	<400> 18						
	gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttgctggct	60
35	tcatgttgat	aactacttta	tatggagctt	cattggacct	gttaccttca	ttattctgct	120
	aaatattatc	ttcttgggtg	tcacattgtg	caaaatgggtg	aagcattcaa	acactttgaa	180
	accagattct	agcaggttgg	aaaacattaa	gtcttgggtg	cttggcgctt	tcgctcttct	240
	gtgtcttctt	ggcctcacct	ggtccttttg	gttgcttttt	attaatgagg	agactattgt	300
	gatggcatat	ctcttcacta	tatttaattg	tttccaggga	gtgttcattt	tcatctttca	360
40	ctgtgctctc	caaaagaaag	tacgaaaaga	atatggcaag	tgcttcagac	actcatactg	420
	ctgtggaggc	ctcccaactg	agagtcccca	cagttcagtg	aaggcatcaa	ccaccagaac	480
	cagtgtctgc	tattcctctg	gcacacagag	tcgtataaga	agaatgtgga	atgatactgt	540
	gagaaaacaa	tcagaatctt	cttttatctc	aggtgacatc	aatagcactt	caacacttaa	600
	tcaaggtggc	ataaatctta	atatattatt	acaggactga	catcacatgg	tctgagagcc	660
45	catcttcaag	atttatatca	tttagaggac	attcactgaa	caatgccagg	gatacaagtg	720
	ccatggatac	tctaccgcta	aatggtaatt	ttacaacacg	ctactcgctg	cacaagggtg	780
	actataatga	cagcgtgcaa	gttggtgact	gtggactaag	tctgaatgat	actgcttttg	840
	agaaaatgat	catttcagaa	ttagtgcaca	acaacttacg	gggcagcagc	aagactcaca	900
	acctcgagct	cacgctacca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960
50	ctattgtggc	agatgcttca	tctttaatgc	acagcgacaa	cccagggtcg	gagctccatc	1020
	caaaagaact	cgaggcacca	cttattcctc	agcggactca	ctccctctctg	taccaacccc	1080
	agaagaaagt	gaagtccgag	ggaactgaca	gctatgtctc	ccaactgaca	gcagaggctg	1140
	aagatcacct	acagtccccc	aacagagact	ctctttatag	aagcatgccc	aatcttagag	1200
	actctcccta	tccggagagc	agccctgaca	tggaagaaga	cctctctccc	tccaggaggga	1260
55	gtgagaatga	ggacatttac	tataaaagca	tgccaaatct	tgagagctggc	catcagcttc	1320
	agatgtgcta	ccagatcagc	aggggcaata	gtgatgggtg	tataatcccc	attaacaaag	1380
	aaggggtgat	tccagaagga	gatgttagag	aaggacaaat	gcagctgggt	acaagtcttt	1440
	aatcatacag	ctaaggaatt	ccaagggcca	catgcgagta	ttaataaata	aagacaccat	1500
	tggcctgacg	cagctccctc	aaactctgct	tgaagagatg	actcttgacc	tgtggttctc	1560
60	tggtgtaaaa	aagatgactg	aaccttgtag	ttctgtgaat	ttttataaaa	catacaaaaa	1620
	ctttgtatat	acacagagta	tactaaagtg	aattatttgt	tacaaagaaa	agagatggcca	1680
	gccaggtatt	ttaagattct	gctgctgttt	agagaaattg	tgaacaagac	aaaacaaaac	1740
	tttccagcca	ttttactgca	gcagctctgtg	aactaaattt	gtaaatatgg	ctgcaccatt	1800
	tttgtaggcc	tgcattgtat	tatatacaag	acgttaggctt	taaaatcctg	tgggacaaat	1860
65	ttactgtacc	ttactattcc	tgacaagact	tggaaaagca	ggagagatat	tctgcatcag	1920
	tttgcagttc	actgcaaatc	ttttacatta	aggcaaaagat	tgaaaacatg	cttaaccact	1980

	agcaatcaag	ccacaggcct	tattttcatat	gtttcctcaa	ctgtacaatg	aactatttctc	2040
	atgaaaaatg	gctaaagaaa	ttatatatttg	ttctattgct	agggtaaaat	aaatacatatt	2100
	gtgtccaact	gaaatataat	tgctattaaa	ataattttta	agagtgaaga	aaatattgtg	2160
5	aaaagctctt	ggttgacat	gttatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
	ctactcattt	tcacttcttt	tccactgtat	acagtgttct	gctttgacaa	agttagtctt	2280
	tattactttac	attttaaattt	cttattgccca	aaagaacgtg	ttttatgggg	agaaacaaac	2340
	tctttgaagc	cagttatgtc	atgccttgca	caaaagtgat	gaaatctaga	aaagattgtg	2400
	tgtcaccctt	gtttattctt	gaacagaggg	caaagagggc	actggggcact	tctcacaaac	2460
	tttctagtga	acaaaagggtg	cctatttctt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
10	actcttccat	attccttctg	cctatattta	gtaatttaatt	tatttttatga	taaagttcta	2580
	atgaaatgta	aattgtttca	gcaaaattct	gctttttttt	catccctttg	tgtaaacctg	2640
	ttaataatga	gcccatcact	aatatccagt	gtaaagttta	acacggtttg	acagtaaata	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaaa	aa			
15	<210> 19						
	<211> 276						
	<212> DNA						
	<213> Human						
20	<400> 19						
	ctccctaaat	gatttttaaaa	taaattggat	aaacatatga	tataaagtg	gtacttttaga	60
	aaccgccttt	gcatattttt	tatgtacaaa	tctttgtata	caattccgat	gttccctata	120
25	tattccctat	atagcaaacc	aaaaccagga	cctcccaact	gcatgcctca	agtccctgtg	180
	gagcactctg	gcaactggat	ggccctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaatt	aaatacctcg	gccgcgacca	cgctgg			
	<210> 20						
	<211> 2361						
30	<212> DNA						
	<213> Human						
	<400> 20						
35	attgtaccag	ccttgatgaa	cgtggggcct	gcttcgcttt	tgagggccat	aagctcattg	60
	cccactgggt	tagaggctac	cttatcattg	tctcccggtga	ccggaagggt	tctcccaagt	120
	cagagttttac	cagcagggat	tcacagagct	ccgacaagca	gattctaaac	atctatgacc	180
	tggtgaacaa	gttcatagcc	tatagcaccg	tctttgagga	tgtagtggtg	gtgcttgctg	240
40	agtggggctc	cctgtacgtg	ctgacgcggg	atgggcgggt	ccacgcactg	caggagaagg	300
	acacacagac	caaactggag	atgctgttta	agaagaacct	atttgagatg	gcgattaacc	360
	ttgccaaagag	ccagcatctg	gacagtgtg	ggctggccca	gattttcatg	cagtatggag	420
	accatctcta	cagcaagggc	aaccacgatg	gggctgtcca	gcaatatatc	cgaaccattg	480
	gaaagttgga	gccatcctac	gtgatccgca	agtttctgga	tgcccagcgc	attcacaacc	540
	tgactgccta	cctgcagacc	ctgcaccgac	aatccctggc	caatgccgac	cataccacc	600
45	tgctcctcaa	ctgctatacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaagtc	cactttgatg	tggagacagc	catcaaggtc	ctccggcagg	720
	ctggctacta	ctcccattgc	ctgtatctgg	cggagaacca	tgacatcat	gagtgttacc	780
	tgaagatcca	gctagaagac	attaagaatt	atcaggaagc	ccttcgatac	atcggcaagc	840
	tgctttttga	gcaggcagag	agcaacatga	agcgtacgg	caagatcctc	atgcaccaca	900
50	taccagagca	gacaactcag	ttgctgaagg	gactttgtac	tgattatcgg	cccagcctcg	960
	aaggccgcag	cgataggagg	gccccaggct	gcaggggcaa	ctctgaggag	ttcatcccca	1020
	tctttgccaa	taaccgcga	gagctgaaag	ccttcctaga	gcacatgagt	gaagtgcagc	1080
	cagactcacc	ccaggggatc	tacgacacac	tccttgagct	gcgactgcag	aactgggccc	1140
	acgagaagga	tccacaggtc	aaagagaagc	ttcacgcaga	ggccatttcc	ctgctgaaga	1200
55	gtggctcgct	ctgcgacgtc	tttgacaagg	ccctggctct	gtgccagatg	cacgacttcc	1260
	aggatgggtg	cctttacctt	tatgagcagg	ggaagctggt	ccagcagatc	atgcactacc	1320
	acatgcagca	cgagcagtag	cggcaggtca	tcagcgtgtg	tgagcgccat	ggggagcagg	1380
	acccctcctt	gtgggagcag	gccctcagct	acttcgctcg	caaggaggag	gactgcaagg	1440
	agtatgtggc	agctgtcctc	aagcatatcg	agaacaagaa	cctcatgcca	cctcttctag	1500
60	tggtgcagac	cctggcccac	aactccacag	ccacactctc	cgtcatcagg	gactacctgg	1560
	tccaaaaact	acagaaacag	agccagcaga	ttgcacagga	tgagctgcgg	gtgcggcggg	1620
	accgagagga	gaccaccggt	atccgcagg	agatccaaga	gctcaaggcc	agtcctaaga	1680
	ttttccaaaa	gaccaagtgc	agcatctgta	acagtgcctt	ggagttgccc	tcagtccact	1740
	tctgtgtgg	ccactccttc	caccaacact	gctttgagag	ttactcggaa	agtgatgctg	1800
65	actgccccac	ctgcctccct	gaaaaccgga	aggatcatgga	tatgatccgg	gccagggaac	1860
	agaaacgaga	tctccatgat	caattccagc	atcagctcaa	gtgctccaat	gacagctttt	1920

	ctgtgattgc	tgactacttt	ggcagaggtg	ttttcaacaa	attgactctg	ctgaccgacc	1980
	ctcccacagc	cagactgacc	tccagcctgg	aggtctgggt	gcaacgcgac	ctactcatgc	2040
	actccaggag	gggcacttaa	gcagcctgga	ggaagatgtg	ggcaacagtg	gaggaccaag	2100
5	agaacagaca	caatgggacc	tggggcggcg	ttacacagaa	ggctggctga	catgcccagg	2160
	gtccactct	catctaattg	cacagccctc	acaagactaa	agcggaaactt	tttcttttcc	2220
	ctggccttcc	tttaattttaa	gtcaagcttg	gcaatccctt	cctctttaac	taggcagggtg	2280
	ttagaatcat	ttccagatta	atggggggga	aggggaacct	caggcaaacc	tcctgaagtt	2340
	ttggaaaaaa	aagctgggtt	c				
10	<210>	21					
	<211>	179					
	<212>	DNA					
	<213>	Human					
15	<400>	21					
	agggtgtaga	tgctcttgaa	aaagaaactg	catctaagct	gtcagaaatg	gattctttta	60
	acaatcaact	aaaggaactg	agagaaacct	acaacacaca	gcagttagcc	cttgaacagc	120
20	tttataagat	caacgtgaca	agttgaagga	aattgaaagg	aaaaaattag	aactaatgc	
	<210>	22					
	<211>	905					
	<212>	DNA					
	<213>	Human					
25	<400>	22					
	tttttttttt	ttctttaacc	gtgtggtctt	tatttcagtg	ccagtgttac	agatacaaca	60
30	caaatgttcc	agtttagaag	aattcaaacg	gaatgccaa	gtccaagcca	ggctcaagaa	120
	ataaaaagg	aggtttgag	taatagataa	gatgactcca	atactcactc	ttcctaagg	180
	caaagggtact	tttgatacag	agtctgatct	ttgaaactgg	tgaactcctc	ttccacccat	240
	taccatagtt	caaacaggca	agttatgggc	ttaggagcac	tttaaaattt	gtgggtgggaa	300
	taggggtcatt	aataactatg	aatatatctt	ttagaagggtg	accattttgc	actttaaagg	360
35	gaatcaattt	tgaaaatcat	ggagactatt	catgactaca	gctaaagaat	ggcgagaaag	420
	gggagctgga	agagccttgg	aagtttctat	tacaaataga	gcaccatata	cttcatgcc	480
	aatctcaaca	aaagctcttt	taaactccat	ctgtccagtg	tttacaataa	aactcgcaag	540
	gtctgaccag	ttcttggtta	caaacataca	tgtgtgtgtc	tgtgtgtata	cagcaatgca	600
	cagaaaaggc	taccaggagc	ctaattgcctc	tttcaaacat	tgggggaacc	agtagaaaaa	660
40	ggcagggctc	cctaattgtcc	attattacat	ttccattccg	aatgccagat	gttaaaagtg	720
	cctgaagatg	gtaaccacagc	tagtgaggaa	ttaatacccc	accttgccca	gtccacagag	780
	aaacaacagt	agaaagaagg	ggcaactctt	tgctgcagag	acaaagttag	tgttttttcg	840
	ccatggattg	cagtcctctc	ctccagacca	gctgcttatt	tcctcagggg	cccagggaat	900
	gttga						
45	<210>	23					
	<211>	2134					
	<212>	DNA					
	<213>	Human					
50	<400>	23					
	ggtctcttct	ttcctttttt	tttttccaaa	agtgttcttt	tatttctagt	aacatatatt	60
	gtataaatac	tctattttat	atgcacttcc	acaaaagcga	tataatttaa	aagttttttt	120
55	cattagaaat	aaatgtataa	aaataaatat	gttattatag	gcattttatta	ctaactatag	180
	tccttcttgg	aaggaacacc	caaaccaata	cttataaagt	acatgtaatt	tatagtaaca	240
	tattttacta	tatacatatg	gaaaaaatca	tattctcaca	gaagagctga	acagacattc	300
	accaggatac	gactgttgga	ccagctgctg	gagatggacc	tgctaccctt	cagcagcttc	360
	cccaccacaa	gacaagtgat	ctcaatgtcc	ccaaacctgt	gggacctgtg	tctacacacc	420
60	tcatttttgt	tccggcgttt	catcctcctt	gtgtgattgt	actgattttc	atgagacaca	480
	agttacttct	ttacatccat	attcccaaag	cagggttaca	tggtaggaaa	gaaaggaagt	540
	tggagggtact	aagctcattg	tgtctcctct	agcttttacc	agcatctaata	gcttctactgc	600
	tttttttcca	ttgtgacttt	taatgcactt	gaataaatac	atggagttgt	tttttctctca	660
	aaatgaatta	cacaaataaa	gactgagatg	gtccaaaaaa	ggaaagagga	agccatttgc	720
65	gttattttcac	gttgctgagc	ctttctctca	tggtgaacaa	tctgaagttt	taattctcgg	780
	tagaaataat	gtataaacat	tctctgaaac	catagcagcc	ataaacagtg	ctgggtcaaa	840
	atcctatttg	tactcctttc	tccccccatt	gttagtgagg	taaagtaaaa	cagggtcttag	900

5 taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtattttgat 960
 aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttgttttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccg ggctttatta 1080
 tgctatatca ctgctcagag gttaataatc ctactaact atcctatcaa atttgcaact 1140
 ggcagtttac tctgatgatt caactccttt tctatctacc ccataatcc caccttactg 1200
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgccttccct 1260
 gcaccagccc ttctcactt tgccttgccc tcaaagctaa caccacttaa accacttaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttctttaaa ggatcacagc 1380
 10 tctcatgaga taacaccctt ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 ggtctgcaca aggtctgggt ctggctgggt tcaacttctt tgcacactcg gaagcaggct 1560
 gtccattaat gtctcgcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 15 ccttcttctt ctttacgaag taggtgtatt taattttagg tcgaagggca ttgccacag 1740
 taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800
 ccgcagagga gccgctgtac ctcaagacaa cacctttgta cataatgtct tgctctaagg 1860
 tggacaaaagt gtatgcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agctgccatt gttcttggat cccctctggt tccgctgttt cacttcgatg ttggtggctc 1980
 20 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040
 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttctttttgg 2100
 agtctatgat gcgatcacia ccagctttta caca

<210> 24

<211> 1626

25 <212> DNA

<213> Human

<400> 24

30 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatattttgg 60
 ttattttgaa tacagacatt ggctccaaat tttcatcttt gcacaatagt atgacttttc 120
 actagaactt ctcaacattt gggaaacttg caaatatgag catcatatgt gtttaggctg 180
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaactg 240
 35 agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300
 gaaaaaggca agacaaatgg cctcttgtac tgaatacttc ggcaacttta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata tttgtagagc ttgctagaa tggattacat 420
 ggtagttagt cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggtttttag 540
 40 aaagctttgt ctaaaaattt ggcctaggaa tggtaaactt attttcagtt gccagggggt 600
 agaaaaataa tatgtgtggt gttatgttta tgtaacata ttattaggta ctatctatga 660
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttggaa ctaggttacc cttgaaggat atgctggcag 780
 ccatctcttt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttggg 840
 45 tctggaatgc attagttatg ccttgtacca tccccagaat ttcaggggca tctgtgggtt 900
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 50 aactaagata tttatctatg aagatataaa tgggtcgagag agactttcat ctgtggattg 1200
 cgttgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtac tgcaatcaca 1320
 atgcccattg gtgtttatgg gctattttgt taagtaagt gtaagatgct atgaagtaag 1380
 tgtgtttgtt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440
 55 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500
 attatactcg tcacgcttct agttgtctca accattttat aaccattttt gtacatattt 1560
 tacttgaaaa tatttttaaat ggaaatttaa ataacattt gatagtttac ataataaaaa 1620
 aaaaaa

<210> 25

60 <211> 1420

<212> DNA

<213> Human

<400> 25

65 gtccagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60

5 ttcattgaaa tccttgctac ttctcttcct cctcaatgaa agacacgaga gacaagagcg 120
 acacaagctt aagaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180
 ttggaaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240
 agtgggaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 300
 tccttgtagt gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360
 tattttataa ggcccataaa tactggttaa actctgttaa aagtgggcct tctatcttgg 420
 atggtttcac tgccatcagc catgctgata tattagaaat ggcaccccta tctacttact 480
 ttaatgctta aaattatata taaaatgctt tatttagaaa acctacatga tacagtgggtg 540
 10 tcagccttgc catgtatcag ttccacttga aatttgagac caattaaatt tcaactgttt 600
 aggggtggaga aagaggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660
 atccttttga tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 720
 tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780
 tttgctctgt tttgctgaa gtttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840
 accagtacct ggggaggtta gatgtgtgtt tcaggcttgg agtgtatgag tgggttttgc 900
 15 tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960
 gtggttttgc ttttttttct caagtataat tgtgaacata tttcctttat aggggcaggg 1020
 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080
 tcgacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttggtt aggttactgt 1140
 20 acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa attttgtttt 1200
 tatagaaatt ttttatactg attggttcac agatggtcag ttttgtacac agactgaaca 1260
 atacagcact ttgccaaaaa tgagtgtagc attgttttaa cattgtgtgt taacacctgt 1320
 tctttgtaat tgggttgttg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380
 agtaataaaa gtgtccttta acttcaaaaa aaaaaaaaaa

25 <210> 26
 <211> 689
 <212> DNA
 <213> Human

30 <400> 26

35 aaacaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60
 caaacaatta tagcacatcc ttctttttac tctgtctcac ctcttttagg tgagtacttc 120
 cttaataaag tgctaaacat acatatacgg aacttgaaag ctttggttag ccttgcccta 180
 ggtaatcagc ctagtattaca ctgtttccag ggagtagttg aattactata aaccattagc 240
 cactgtcttc tgcaccattt atcacaccag gacagggtct ctcaacctgg gcgctactgt 300
 catttggggc caggtgattc ttcttgcgaa gggctgtcct gtacctgccc gggcgggccc 360
 tcgaagcgtg gtcgcggccg aggtactgaa aggaccaagg agctctggct gccctcagga 420
 40 attcacaatg accgaaggaa caaagcttca gggctctggg tgggtgtctcc cactattcag 480
 gaggtggctg gaggtaacgc agcttcattt cgtccagtc tttccagtat ttaaagttgt 540
 tgccaagatg ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600
 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660
 cacaccacaga gcctgaagtt tgtccttcg

45 <210> 27
 <211> 471
 <212> DNA
 <213> Human

50 <400> 27

55 tcccagcggc atgaagtttg agattggcca ggcctgtac ctgggcttca tctccttcgt 60
 ccctctcgct cattggtggc accctgcttt gcctgtcctg ccaggacgag gcaccctaca 120
 agccctaacc caggcccccgc ccaggggccac cagcaccact gcaaacaccg cacctgccta 180
 ccagccacca gctgcctaca aagacaatcg ggccccctca gtgacctcgg ccaccacagc 240
 gggtagcagg tgaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggctgctg 300
 tgggctgggt cccggcgggg ctgtcaatgg aggcaggggt tccagcacaa agtttacttc 360
 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420
 60 ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

65 <210> 28
 <211> 929
 <212> DNA
 <213> Human

<400> 28

	ggtgaactca	gtgcattggg	ccaatgggtc	gacacaggct	ctgccagcca	caaccatcct	60
	gctgcttctg	acggtttggc	tgctgggtgg	ctttcccctc	actgtcattg	gaggcatcct	120
5	tggaagaac	aacgccagcc	cctttgatgc	accctgtcgc	accaagaaca	tcgcccgga	180
	gattccacc	cagccctgg	acaagtctac	tgatccac	atgactgttg	gaggcttcct	240
	gcctttcagt	gccatctctg	tgagctgta	ctacatcttt	gccacagtat	ggggtcgga	300
	gcagtacact	ttgtacggca	tcctcttctt	tgtcttcgcc	atcctgctga	gtgtgggggc	360
	ttgcatctcc	attgcaactc	cctacttcca	gttgtctggg	gaggattacc	gctgggtggg	420
	gcgatctgtg	ctgagtgttg	gctccaccgg	cctcttcac	ttcctctact	cagttttcta	480
10	ttatgcccg	cgctccaaca	tgtctggggc	agtacagaca	gtagagtctt	tcggctactc	540
	cttactcact	ggttatgtct	tcttctcat	gctgggcacc	atctcctttt	tttcttccct	600
	aaagtctc	cggtatatct	atgttaacct	caagatggac	tgagtctgtg	atggcagaac	660
	tattgctgtt	ctctcccctt	cttcatgccc	tggtgaactc	tcctaccagc	ttctctctg	720
	attgactgaa	ttgtgtgatg	gcattgttgc	cttccccttt	tccctttggg	cattccttcc	780
15	ccagagaggg	cctggaaatt	ataaatctct	atcacataag	gattatata	ttgaactttt	840
	taagttgcct	ttagttttgg	tcctgatttt	tctttttaca	attacaaaa	taaaatttat	900
	taagaaaaag	aaaaaaaaaa	aaaaaaaaaa				
	<210> 29						
20	<211> 1775						
	<212> DNA						
	<213> Human						
	<400> 29						
25							
	gaacgtgatg	ggaacttttg	gaggatgtct	gagaaaaatg	ccgaagggat	tttggccaac	60
	accagaaaac	gccaatgtcc	taggaattcc	ctcccaaaat	gcttcccaaa	aaattactca	120
	ttgacaattc	aaattgcact	tggtggcg	cagcccgggc	ggccttcagt	ccgtgtgggg	180
30	cgcccgctg	gccttctcct	cgtaggactc	ccaaaactcg	ttcactctgc	gtttatccac	240
	aggataaagc	caccgctgg	acaggtagac	cagaaacacc	acgtcgtccc	ggaagcaggc	300
	cagccgggtg	gacgtgggca	tggtgatgat	gaaggcaaa	acgtcatcaa	tgaaggtgtt	360
	gaaagccttg	taggtgaagg	ccttccagg	cagatgtg	actgacttca	acttgtagtt	420
	cacaaagagc	tggggcagca	tgaagaggaa	accaaaggca	tagaccccg	tgacgaagct	480
	gttgattaac	caggagtacc	agctcttata	tttgatatte	aggagtgaat	agacagcacc	540
35	cccgcacag	agagggtaca	gcaggtagat	caagtacttc	atggcctgag	tatcgtactc	600
	cctgggtttc	ctctcagatt	cgctgtaagt	gccaactga	aattcgggca	tcaggcctct	660
	ccaaaaata	gtcatcttca	atgccttctt	cactttccac	agctcaatgg	cggtcccaac	720
	accgcgggg	accagcacca	gcaggctcgt	ctgctcgtcc	agcaggaaca	gaaagatgac	780
40	cacggtgctg	aagcagcgcc	agagcactgc	cttggtggac	atgccgatca	tgctcttctt	840
	cttcttccag	aaactgatgt	catttttaaa	ggccaggaaa	tcaaagagaa	gatggaacgc	900
	tgcgacaaag	aaggtcagcg	ccaggaagta	taagttggta	tctacaaaaa	ttcctttcac	960
	ctcatcagca	tctttctctg	aaaaccggaa	ctgctgcagg	gagtacacgg	cgctctgcat	1020
	gtggatccag	aagcgcagcc	gccccagtg	gacctgtctg	taggacacgg	tgaggggcag	1080
45	ctcggtgggtg	gagcggttta	tgaccatcag	gtccttcacg	cggttgctga	gctggctgat	1140
	gaacaggatg	ggcaggtaat	gcacggtttt	ccccagctgg	atcatcttca	tgtaccgatg	1200
	cacatcggga	ggcaggggag	accctgcaaa	gacaaagtgt	tccgccatca	cggtcagcgc	1260
	cagcgcgggt	cgccagtg	acactggctc	atccagggca	ctcgtcggct	tcttctccgc	1320
	ctcgatctgc	tgtgtatcag	actccccggt	gagcagggtg	atttcttctg	gcttggggac	1380
50	catgtaggtg	gtcagaggac	tgaccagggtg	cacctgcttc	ccgtcgtgcc	acggcaggac	1440
	cccagcgtga	tgagggaaga	tgtaggcata	cagcgtccca	ttgtttctcg	ttttctttgg	1500
	tacagaaaca	ttactgtcc	tttcaaattt	ggactccaca	tcaaagtctt	ccacattcaa	1560
	gaccaggtcg	atgttgttct	cagcaccag	gtgggacctc	gtcgtgggtg	acacgtcag	1620
	ctgcagcttg	ggccgcccgc	ccaggtagg	ctggatgcag	ttggcgtcgc	cggagcacgg	1680
55	gcgggtgtag	acgatgccgt	acatgaccca	gcagggtgtg	accacgtaga	ccacgaacac	1740
	gccaccacc	aagctgggtg	aggagctg	gcccc			
	<210> 30						
	<211> 1546						
	<212> DNA						
60	<213> Human						
	<400> 30						
65	aaaataagta	ggaatgggca	gtgggtattc	acattcacta	caccttttcc	atttgcta	60
	aaggccctgc	caggctggga	gggaattgtc	cctgctgct	tctggagaaa	gaagatattg	120

5 acaccatcta cgggcacat ggaactgctt caagtgaacca ttctttttct tctgcccagt 180
 atttgcagca gtaacagcac aggtgtttta gaggcagcta ataattcact tgttggtact 240
 acaacaaaac catctataac aacaccaaac acagaatcat tacagaaaaa tgttgtcaca 300
 ccaacaactg gaacaactcc taaaggaaca atcaccaatg aattacttaa aatgtctctg 360
 atgtcaacag ctactttttt aacaagtaaa gatgaaggat tgaaagccac aaccactgat 420
 gtcaggaaga atgactccat ctttcaaac gtaacagtaa caagtgttac acttccaaat 480
 gctgtttcaa cattacaaag ttccaaaccc aagactgaaa ctcagagttc aattaaaaa 540
 acagaaatac caggtagtgt tctacaacca gatgcatcac cttctaaaac tgggtacatta 600
 10 acctcaatac cagttacaat tccagaaaac acctcacagt ctcaagtaat aggcactgag 660
 ggtggaaaaa atgcaagcac ttcagcaacc agccgggtctt attccagtat tattttgccc 720
 gtggttattg ctttgattgt aataacactt tcagtatttg ttctggtggg ttgtaccga 780
 atgtgctgga aggcagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840
 aaagagagcg tgaagcttct taccgttaag acaattttctc atgagtctgg tgagcactct 900
 gcacaaggaa aaaccaagaa ctgacagctt gaggaattct cccacacact aggcataat 960
 15 tacgttaat cttcagcttc tatgcaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020
 aatcccagat tccataacct ctgctggact gtaccagacg tctgtcccag taaagtgatg 1080
 tccagctgac atgcaataat ttgatggaat caaaaagaac ccgggggtc tccgtttctc 1140
 tcacatttaa aaattccatt actccattta caggagcgtt cctaggaaaa ggaattttag 1200
 20 gaggagaatt tgtgagcagt gaatctgaca gccaggagg tgggctcgct gataggcatg 1260
 actttcctta atgttttaaag tttccgggc caagaatttt tatccatgaa gactttccta 1320
 cttttctcgg tgttcttata ttacctactg ttagtattta ttgtttacca ctatgttaat 1380
 gcagggaaaa gtgacagtg tattattaaa tattaggtag aaatcatacc atgctacttt 1440
 gtacatataa gtatttttatt cctgctttcg tgttactttt aataataaac tactgtactc 1500
 25 aataactctaa aaatactata acatgactgt gaaaatggca aaaaaa

<210> 31
 <211> 750
 <212> DNA
 <213> Human

30 <400> 31

35 cacttgggca cccccatttt ctaaaaaat ggaaatctgg agggcaaaaa aggtgtgctg 60
 aagggaagtg cctctgatgg cccaaaaacc ttcttccaaa ctagtgtagg aatggaatgg 120
 atagcaaatg gatccttttt ggcctccttt ggagcatgcc ttccctatct tatccttggc 180
 cccactaaag cagaacgtta cggatatttc tgtttttgcc attggatgcc tatctggcca 240
 aacagccttt ccctaattgg aaaatgcagt cctgtttaaa acctttgatt tacgactact 300
 40 tgtatcatgct tgctcattac aattttgaca ttttttacct agtgaagacc ccaaacatat 360
 cagtgaacaa tgacaagatc ataaagaaca gtatcatatt attatttagt cgcttttaca 420
 gtggcaagcc aattttgaaa tatctcattt aaaactcaga cccaattcac tgagtatac 480
 ttttaatagc ttctcagca cactatttcc catgcattaa atatgataaa ataacttatc 540
 actgcccatac ggtcctgtta aaaggaagtc tgaatacaga gccacaaca ctaaaattgt 600
 ttttctagct acaaaagtata gcatcatcaa cacagacacg atttggtact cctgacaggt 660
 45 ggattggaaa acggtgttta aagagaagag aacattttta cataaatgtc attaagaatc 720
 ccaaaggcct tatttgcac caccgtcccg

<210> 32
 <211> 1620
 <212> DNA
 <213> Human

50 <400> 32

55 gcaattcccc cctcccacta aacgactccc agtaattatg tttacaaccc attggtatgca 60
 gtgcagccat tcataagaac cttggtgccc cagaaaaatc tgtccctttt ggtaccaaac 120
 ctgaggtctt ttggaagata atgtagaaaa ccactaccta ttgaaggcct gttttggcta 180
 atctgtgcaa actctgatga taactgcctt tctgtgattc tttccacac tgetttcatt 240
 ttttaagtata aagacttaga aaactagaat aatgtcttta caaataatta aaagtatgtg 300
 60 atgttctggg ttttttcect ctttttagaa ccccgctccc atttaaaaaa ttaaaaaaaa 360
 aaaaaaaact ttttaacattt aaaaaataaa aattaacaaa atttacttta ttccaggaca 420
 cgctggcatt tggactcaat gaaaagggca cctaaagaaa ataaggctga ctgaatgttt 480
 tccataattt tcacacaata acagtcctct tctatccagc ttgccttcca tttatctcta 540
 gggtagctt ttcaggcaac atccttggtc attgcccaga aagtacctga gctatcagtg 600
 attggaatgg cacaggaaac cgaatcacat ggggtgccct cccttggttt tcaagtatct 660
 65 tggagttgtg cacaaaaatt aggtcatgcc ttcagtgtct tgttctttaa acctaccctt 720
 tgacaatcag gtgctaataa ttgtatacta ttaaaaccag cacataagta ttgtaaatgt 780

	gtgttcctcc	taggttggaa	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgatttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcatcc	tcgatgatat	tctcactttg	960
5	tcgcaaatct	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
	cagtattatg	tttacaatcc	attggatgag	tgccagcatta	taagaccttg	gtgcccagaa	1080
	aaatctgtcc	tttttggtag	caaacctgag	gtcttttggg	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaattctg	tgcaaacctc	gatgatacct	gcttatgtgg	1200
	attcttttcc	acactgcttt	cattttttaag	tataaagact	tagaaaacta	gaataatgct	1260
10	tttacaataa	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaacctgt	1320
	atttaaaca	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cctctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatttg	tgttccta	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaaat	gtgtaactta	agggtattat	atatataaat	1560
15	acatatatac	ctttgtaacc	tttatactgt	aaataaaaaa	gttgctttag	tcaaaaaaaa	1620
	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
20	<400> 33						
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
25	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gtgaaaaagg	tgtagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaagttaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgac	ggactaaaga	agaaagggct	tatgacaaag	caaaacggag	gattgagaaa	300
	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
30	gtacttgggc	atgtggacac	agggaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tggtatcaca	caacaaattg	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtacggatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccatttta	gttgttgata	ttatgcatgg	tttgagagccc	660
35	cagacaattg	agtctatcaa	ccttctcaaa	tctaaaaaat	gtcccttcat	tgttgcactc	720
	aataagattg	ataggttata	tgattggaaa	aagagtcctg	actctgatgt	ggctgctact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	ctttggtacc	tacctctgca	catactgggt	atggcatggg	aagtctgatc	960
40	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgca	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgct	1080
	atcttgatca	atgggcgttt	gaaggaagga	gatacaatca	ttgttctctg	agtgaagg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctctc	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	agggggtaaa	gattcttgga	1260
45	aaagacctgg	agaaaacatt	ggctgggtta	cccctccttg	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctcactctg	gttcttttga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccttat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
50	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttaga	1620
	atttttagtg	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcga	gatccgatag	tgatgggggt	gacgggtggaa	1800
	gcaggtcagg	tgaacagggg	gacacccatg	tgtgtcccaa	gcaaaaattt	tggtgacatc	1860
55	ggaatagtaa	caagtattga	aataaaccat	aaacaagtgg	atggtgcaaa	aaaaggacaa	1920
	gaagtttgtg	taaaaataga	acctatccct	ggtgagtcac	ccaaaatgtt	tggaagacat	1980
	tttgaagcta	cagatatctc	tgttagtaag	atcagccggc	agtccattga	tgcaactcaa	2040
	gactggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttgaaa	tcattctaatt	ttttcacatg	gagcaggaac	tggagtaaat	gcaatactgt	2160
60	gttgtaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tgggaaggaag	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	gggttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggtctg	tgttttaaag	tttgcccttc	2400
	cccaaatttg	gattttttatt	acagatctaa	agctctttcg	attttatact	gattaaatca	2460
65	gtactgcagt	atttgattaa	aaaaaaaaaa	gcagattttg	tgattcttgg	gacttttttg	2520
	acgtaagaaa	tacttcttta	tttatgcata	ttcttccac	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700
 agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760
 catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
 5 ggtatgccag cacctgggta acagtaggag attttatata ttaatctgat ctgtttaatc 2940
 tgatcgggtt agtagagatt ttatacat

<210> 34

<211> 6011

10 <212> DNA

<213> Human

<400> 34.

15

acggggcgcc ggacgaccgc cacatcttat cctccacgce ccactcgcac tgggagcggg 60
 20 accgcccccg actccccctc gggccggcca ctcgaggagt gaggagagag gccgcccggc 120
 cggtctgagc cgagcgcagc accccccgcg ccccgcgcca gaagtttggg tgaaccgggc 180
 tgccgggaga aacttttttc tttttccccc ctctcccggg agagtctctg gaggaggagg 240
 ggaaactcccc cgccccaaag ctcgtgggct cggggtcgcg cggccgcaga aggggcccgg 300
 tccgcccgcg aggggaggcg cccccgggga cccgagaggg ggggtaggac cgcgggctgc 360
 25 tggccgggct gcggcagcgt gtgcccgcg caggggaggc gccgccccgc tcccggcccc 420
 gctgcgagga ggaggcggcg gcggcgcagg aggatgtact tgggtggcggg ggacaggggg 480
 ttggccggct gcgggcacct cctggtctcg ctgctggggc tgctgctgct gccggcgcgc 540
 tccggcaccc gggcgctggt ctgcctgccc tgtgacgagt ccaagtgcga ggagcccagg 600
 aaccgcccgc ggagcatcgt gcagggcgtc tgcggctgct gctacacgtg cgcagccag 660
 30 gggaacgaga gctgcggcgg cactctcggt atttacggaa cctgcgaccg ggggctgctg 720
 tgtgtcatcc gcccccgct caatggcgac tccctcaccg agtacgaagc gggcgtttgc 780
 gaagatgaga actggactga tgaccaactg ctgggtttta aaccatgcaa tgaaaacctt 840
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
 aatccctttg agtttccaag tcaggatatg tgcctttcag ctttaaagag aattgaagaa 960
 35 gagaagccag attgtccaa ggcccgtgt gaagtccagt tctctccacg ttgtcctgaa 1020
 gattctgttc tgatcgaggg ttatgtctct cctggggagt gctgtccctt acccagccgc 1080
 tgcgtgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
 ctagtgtcaa aagcctcagg gaagccggga ggtgctgtg acctctatga gtgcaaacca 1200
 gttttcggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
 40 ccggacagct atgaaactca agtcagacta actgcagatg gttgctgtac tttgccaaaca 1320
 agatgcgagt gtctctctgg cttatgtggt ttccccgtgt gtgaggtggg atccactccc 1380
 cgcatagtct ctggtggcga tgggacacct ggaaagtgt gtgatgtctt tgaatgtgtt 1440
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560
 45 cagtgtgggt agataaactg cgagaggtag tacgtgcccg aaggagagtg ctgcccagtg 1620
 tgtgaagatc cagtgtatcc ttttaataat cccgctggct gctatgccaa tggcctgatc 1680
 cttgcccacg gagaccgggt gcgggaagac tagtcacat tctgccagtg cgtcaacggt 1740
 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860
 50 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920
 cacaatgggt gtcggacctg tcagtgcata aacaccaggg aactatgttc agaacgtaaa 1980
 caaggctgca ccttgaactg tcccttcggg ttccctactg atgcccataa ctgtgagatc 2040
 tgtgagtggc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
 cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
 55 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttatc 2220
 tgcaagtgca gagaggcctc tgcttcagct gggccaccca tectgtcggg cacttgtctc 2280
 accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
 tactgtctca atggacggga aatgtgtgcc ctgacacct gcccggtgcc tgccgtgtgc 2400
 aacccccacca ttcaccctgg acagtgtgc ccatcatgtg cagatgactt tgtggtgcag 2460
 60 aagccagagc tcagtactcc ctccatttgc cagcggcctg gaggagaata ctttgtggaa 2520
 ggagaaacgt ggaacattga ctctgtact cagtgcacct gccacagcgg acgggtgtct 2580
 tgtgagacag aggtgtgcc accgtgtct cctcagcaacc cctcagcac ccaggattcc 2640
 tgctgccac agtgtacaga tcaacctttt cggccttcc tgtcccgcga taacagcgta 2700
 cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
 65 gacgtttgta ccagctgcat ctgcattgat agcgttaatta gctgtttctc tgagtcctgc 2820
 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgttgtcc ctactgcata 2880
 aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

	gagcgggtggg	accttgacag	ctgcacccac	tgctactgcc	tgcaggggcca	gacctctctgc	3000
	tcgaccgta	gctgcccccc	tctgccctgt	gttgagccca	tcaacgtgga	aggaagtgtgc	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
5	aacctcgag	gagaggttga	cctggagggt	ccctctgtgc	ccacgcctag	tgaaaatgat	3180
	atcgctccatc	tccctagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaagtg	aagattcttc	actggactcc	attgcctcag	ttgtggttcc	cataattata	3300
	tgctctctcta	ttataatagc	attcctattc	atcaatcaga	agaaacagtg	gataccactg	3360
	ctttgtctggt	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
10	gactgcaaga	aaggaaccag	agtccagggtg	gacagttccc	agagaatgct	aagaattgca	3480
	gaaccagatg	caagattcag	tggtctctac	agcatgcaaa	aacagaacca	tctacaggca	3540
	gacaatttct	accaaacagt	gtgaagaaag	gcaactagga	tgaggtttca	aaagacggaa	3600
	gacgactaaa	tctgctctaa	aaagtaaaact	agaatttgtg	cacttgctta	gtggattgta	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttactgg	gatgggctct	gtctacagca	3720
	atgtgcagaa	caagcattcc	cacttttcct	caagataact	gaccaagtgt	tttcttagaa	3780
15	ccaaagtttt	taaagtgtgct	aagatatatt	tgctgtgaag	atagctgtag	agatatttgg	3840
	gggtggggaca	gtgagtttgg	atggggaaag	gggtgggagg	gtggtgttgg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctggg	aacataaaag	cagttcagtg	gccagagggt	3960
	tatttttttc	ctattgctct	gaagactgca	ctgggtgctg	caaagctcag	gcctgaatga	4020
20	gcaggaaaca	aaaaaggcct	tgcgaccocag	ctgccataac	caccttagaa	ctaccagacg	4080
	agcacatcag	aaccttttga	cagccatccc	aggtctaaag	ccacaagttt	cttttctata	4140
	cagtcacaac	tgcagttagc	agtgaggaag	ccagagaaat	gcgatagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gcttttattt	tcttccaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
25	atgtgagcac	tggagctttt	tttttttaca	acgtgacagg	aagaggaggg	agaggggtgac	4380
	gaacaccagg	catttccagg	ggctatatatt	cactgtttgt	tggtgtcttg	ttctgttata	4440
	ttgttgggtg	ttcatagttt	ttgttgaagc	tctagcttaa	gaagaaactt	tttttaaaaa	4500
	gactgttttg	ggattctttt	tccttattat	atactgattc	tacaaaaatag	aaactacttc	4560
	attttaattg	tatattatc	aagcaccttt	gttgaagctc	aaaaaaaaatg	atgcctcttt	4620
30	aaacttttagc	aattatagga	gtatttatgt	aactatctta	tgcttcaaaa	aacaaaagta	4680
	tttgtgtgca	tgtgtatata	atatatatat	atacatatat	atttatacac	atacaattta	4740
	tgttttctctg	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaggca	gataaacagg	4800
	cattccatag	cagtgctttt	gatcactttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagtat	gtatgtgtgt	gtgtgtgtgt	4920
35	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggt	4980
	attccttttat	taaaatcttc	ctcattttga	tttgctttca	gttggttttc	aatttgcctca	5040
	ctggccagag	acattgatgg	cagttcttat	ctgcactcact	aatcagctcc	tggtttttt	5100
	tttttttttt	tcaaacaatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttggtg	tagtatgcct	caaataataac	tgactgtata	ctatagtggg	aacttttcaa	5220
40	acagccctta	gcacttttat	actaattaac	ccatttgtgc	attgagtttt	cttttaaaaa	5280
	tgcttgttgt	gaaagacaca	gataccaggt	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaaag	gaactttcaa	gtattgttgt	aaatacttgg	acagagggtg	ctgaacttta	5400
	aaaaaaatta	attttattat	ataatgacct	aattttattaa	tctgaagatt	aaccattttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aaggtgttct	agctgtttgc	atcaaaggaa	5520
45	aaaaagattt	attatcaagg	ggcaatattt	ttatcttttc	caaaataaat	ttgttaatga	5580
	tacattacaa	aaatagattg	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
	cattcctggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	ttgttttttt	5700
	caatcatggc	catattatga	aaataactaac	aggatatagg	acaagggtga	aattttttta	5760
	ttattatttt	aaagatatga	tttatcctga	gtgctgtatc	tattactctt	ttactttggg	5820
	tcctgtttgtg	ctcttgtaaa	agaaaaatat	aatttcctga	agaataaaaat	agatatatgg	5880
50	cacttggagt	gcatcatagt	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
	aaaaaaaaa	a					
55	<210>	34a					
	<211>	1036					
	<212>	DNA					
	<213>	Human					
60	<400>	34a					
	mylvagdrgl	agcghllvsl	lgllllpars	gtralvclpc	deskceprn	rpgsivqgvc	60
	gccytcasgg	nescggtfgi	ygtcdrglrc	virpplngds	lteyeagvce	denwtddqll	120
65	gfkpcnenli	agcnlingkc	ecntirtcsn	pfefpsqdmc	lsalkrieee	kpdcskarce	180
	vqfsprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpgc	240

5 ccdlyeckpv fgvdertvec ptvqqtacpp dsyetqvrllt adgcctlptr ceclsglcgcf 300
 pvcevgstpr ivsrgdgtpp kccdvfecvn dtkpacvfnv veyydgdmdfr mdncrfrcrcq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceep iitvdppacg elsncctlirk 480
 dcingfkrdh ngcrtcqcin tqelcserkq gctlnpcpfgf ltdagnceic ecrprpkkr 540
 piicdkycpl gllknkhgdc icrcckcpel scskicplgf qgdshgcllc kcreasasag 600
 ppilsgtclt vdghhhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfvge etwnidsctq ctchsgrvlc etevcppllc 720
 qnpsrtqdsq cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkp d vctscicids 780
 10 viscfscscp svscerpvlr kgqccpycik dtipkkvvch fsgkayadee rwdldsthe 840
 yclqggtlcs tvscplpcv epinvegsc pmcpemyvpe ptnipiekt hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiliic lsiiiaflfi 960
 nqkkqwipll cwyrtptkps slnnqlvsvd ckgktrvqv d ssqrmrlrae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35

<211> 716

<212> DNA

20 <213> Human

<400> 35

25 gcagtagctg gagtgtcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60
 acccggggct cctggggcgc tctgcccggg tggggctgag cagcgatcct gctttgtccc 120
 agaagtcagc agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
 30 ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300
 ttgagggaat ctctgatttc tccttatatg acctcaaaact gaccatacta aacagtgtag 360
 aaggctcttt taaggctcta aatgtcaggg tctccatccc cctgatgcct gacttgtaga 420
 gtcagtgtgg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggt ctttaagacc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 tctggttagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600
 35 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36

<211> 395

40 <212> DNA

<213> Human

<400> 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaaa 180
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
 gccagtaaaa accaaagtca gggttaacaa tgtcatttta caaaatgtta aaaccctaata 300
 50 tgcagttcct tttttaaaatt attttaaaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37

<211> 134

55 <212> DNA

<213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtaacttt taccaccgaa ttgttcactt gactttaaga 60
 aaccataaaa gctgcctggc tttcagcaac aggcctatca acaccatggg gactctccat 120
 aagggaacac gtgt

<210> 38

65 <211> 644

<212> DNA

<213> Human

<400> 38

5 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
 cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
 gggaagagtg ccagtgccgc cactgttaca attcaagatc ttgatctata tccatagatt 180
 ggaatattgg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
 gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
 10 tticagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaaga 360
 aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
 ttgcgaccgg aaaatgtagc ttcccggtta agtaccttgg ccatgtagaa gttgatgaat 480
 caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540
 tcaaaggctt ctttggaaaa actggaaaaga aagcagttaa agcagtttct gtgggtctaa 600
 15 gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

ctttttgttt gggttttcca atgtagatgt ctcagtgaata tgtgcagata tactttgttc 60
 25 cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
 gcctcccacg taactctctt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
 tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
 acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
 agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaaattc 360
 30 tggtcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
 ttttttgttt tttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaacagct 480
 aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
 taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
 atgtttgctt caatagaaat ttgttcccac ttgtattttc aacaaaatta tcggaac

35

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

acaattttta aataactagc aattaatcac agcatatcag gaaaaagtag acagttagtt 60
 45 ctggttagtt tttgtaggct cattatggtt agggctggtt agatgtatat aagaacctac 120
 ctatcatgct gtatgtatca ctcattccat tttcatgttc catgcatact cgggcatcat 180
 gctaataatgt atccttttaa gcactctcaa ggaacaaaaa gggcctttta tttttataaa 240
 ggtaaaaaaa attcccaaaa tttttgcac tgaatgtacc aaagggtgaag ggacattaca 300
 atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
 50 acttcttcca cagtgcctgt tctaccacta caaggactgt gcatctaagt aataattttt 420
 taagattcac tatatgtgat agtatgatat gcattttattt aaaatgcatt agactctctt 480
 ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540
 gctttttatt tgtacagcat cattaacac taagctcagt taaggagcca tcagcaaacac 600
 tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaatgaa 660
 actcagaact atattttctaa gcctgcattt tcaactgatgc ataattttct tagtaattt 720
 55 aagagacagt ttttctatgg catctccaaa actgcattgac atcactagtc ttactcttgc 780
 ttaattttat gagaaggat tcttctattt aattgctttt gggattactc cacatctttg 840
 tttatttctt gactaatcag attttcaata gagtggaagt aaattggggg tcataaaagc 900
 attggattga catatggttt gccagcctat ggggtttacag gcattgccca aacatttctt 960
 tgagatctat atttataagc agccatggaa ttctattat gggatgttgg caatcttaca 1020
 60 ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
 gtgagttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttactc 1140
 ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggg tatagaaatc 1200
 tggaaaataa aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
 65 ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
 tgaaaaaa

<210> 41
 <211> 987
 <212> DNA
 <213> Human

5

<400> 41

```

aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaacat 60
tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtgg 120
10 taacccccgg ctatcagtcg ggatggttgc caccctcctt gctgtaggat ggaagcagcc 180
atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240
tggttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300
tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagggtggag ggtcttcattg 360
aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420
15 ggaggaggga ggagctggta gggagatgct ggctttacct aagggtctga aacaaggagg 480
gcagaatagg cagaggcctc tccgtcccag gccatttttt gacagatggc gggacggaaa 540
tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
gaacaagcac aggccttggg atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
20 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggatatcaa 780
aatagtctac ggccatacca ccctgaacgt gcctaacttc gtaagctaag cagggtcagg 840
cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagttag 900
actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960
tgaagttagc atttggtgtg aaaaaaa

```

25

<210> 42
 <211> 956
 <212> DNA
 <213> Human

30

<400> 42

```

cggacgggtg gggcgacgcg tgggtgcagg agcagggcgg ctgccgactg ccccaaccaa 60
35 ggaaggagcc cctgagtcgg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180
tcaggggatg tttacctggt gctcgggaag ggaggggaag gggccgggga gggggcacgg 240
caggcgtgtg gcagccacac gcaggcggcc agggcggcca gggacccaaa gcaggatgac 300
cagcacctc cagccactg cctccccga atgcatttgg aaccaaagtc taaactgagc 360
tcgcagcccc cgcgcctcc ctccgcctcc catcccgctt agcgtcttgg acagatggac 420
40 gcaggccctg tccagccccc agtgcgetcg ttccgggtccc cacagactgc cccagccaac 480
gagattgtcg gaaaccaagt caggccaggg gggcgacaaa aagggccagg tgcggcctgg 540
ggggaacgga tgctccgagg actggactgt tttttcaca catcgttggc gcagcgggtg 600
gaaggaaagg cagatgtaaa tgatgtgttg gtttacaggg tatatttttg ataccttcaa 660
tgaattaatt cagatgtttt acgcaaggaa ggacttacc agtattactg ctgctgtgct 720
45 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780
tcgcaggacc aagggggcgg ggaactgctg ctcacgcccc gctgtgtcct ccctccctc 840
ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtgg 900
ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

```

50

<210> 43
 <211> 536
 <212> DNA
 <213> Human

55

<400> 43

```

aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
ccctagtttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
60 agtgtttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
tctaaataaa gacatttgaa gggtttagtt gaattctaaa agtaggtaat agccaaatag 300
cattctcadc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaa 360
attttttcca gatgaaactt gtgccacttc caattgacta atgaaataca aggagacaga 420
ctggaaaaaag tgggttatgc cacctttaaa accctttctg gtaaatatta tggtagctaa 480
65 agggtaggtt ccccggcacc tggacctgga caggtagggg tccgtgggta accagt

```


<210> 44
<211> 1630
<212> DNA
<213> Human

5

<400> 44

10 ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180
atccccctcg gaggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240
ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
gtgatttccc ttaggccag gacttgggcc tccagctcat ctgttccctc tgggcccatt 360
catggcagggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
15 gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600
attaggaagt cgggggtggg tgggtgggtgg gggctagtgg gggttgaatt taggggccga 660
tgagcttggg tacgtgagca ggggtgttaag ttaggggtctg cctgtatttc tgggtcccctt 720
20 ggaaatgtcc ccttcttcag tgtcagacct cagtcccagt gtccatatcg tgcccagaaa 780
agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctggg 840
gccagtgac ctgggggagc ctggctgcag gccctcactg gttccctaaa ccttgggtggc 900
tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960
gagttggctg gtagagcctt ctagagggttc agaattattag cttcaggatc agctgggggt 1020
25 atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
tgagggacag tttgggtttg ggacttacca ggggtgatgtt agatctggaa cccccaagtg 1140
aggctggagc gagttaaggc cagtatggaa gatagggttg ggacaggggtg ctttggaatg 1200
aaagagtgc cttagagggc tccttgggcc tcaggaatgc tcctgctgct gtgaagatga 1260
gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320
30 ctgggtccct tgtagcacag gagactgggg ctaaggggccc ctcccaggga agggacacca 1380
tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccagagg 1440
actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgccctg gctgttctct 1500
cattgtcact gccctctccc caacctctcc tctaaccacac tagagattgc ctgtgtcctg 1560
35 cctcttgccct cttgtagaat gcagctctgg ccctcaataa atgcttccctg cattcatctg 1620
caaaaaaaaa

<210> 45
<211> 169
<212> DNA
<213> Human

40

<400> 45

45 tcttttgett ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
taaaactggt ttatgatctt cagtctgatt ccagtgtctg ataactagat aacgtatgaa 120
ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaga cttagttga

<210> 46
<211> 769
<212> DNA
<213> Human

50

<400> 46

55 tgcagggtcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcgggtgga 60
atttgcgctt ttcacttttt ataaagtgtc acataaaatg tcatatttcc aaatttataa 120
acataactcc agttcttacc atgagaacag catgggtgatc acgaaggatc ttcttgaaaa 180
aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240
60 aaggtgtact aggcattctt agagatctgg caacttattt tataataaag gcatctgtga 300
ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
cttcataata tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
ggccagctcc ttctctgata gtctgattct gccctcatat ataggcagct cctgatcatc 480
catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540
tattttgtaa taaaatcaaa tttcccattg aaaccttcaa aaactttgca gaatgagggt 600
65 ttgatatatg tgtacaagta gtaccttctt agtgcagaaa aacatcatta tttctgtctg 660
cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47
 <211> 2529
 <212> DNA
 <213> Human

<400> 47

```

10  ttttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60
    gtgaaaatta gtgactggtt aaggtgtgcc actgtacata tcatcatttt ctgactgggg 120
    tcaggacctg gtcctagtcc acaagggtgg caggaggagg gtggaggcta agaacacaga 180
    aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
    ggatggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
15  gccttactta gctcctggca gaggggtgagt ggggacctac gaggttcaaa atcaaatggc 360
    atttggccag cctggcttta ctaacagggtt cccagagtgc ctctgttggc tgagctctcc 420
    tgggtcactt ccatttccatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480
    attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540
    actagtgtgg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
20  ccagaggccc ctgcaacttt gcggatttcc agaagtgat aaaaagagca ctcttgagt 660
    ggtgcccagg aatgttttaa atctatcagg cacactataa agctggtggt ttcttcctac 720
    caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780
    tgaactctgg tgttgacagg tacaaaggag aagagatggg gactgtgaag aggggagggc 840
    ttccctcctc ttctcacaaga tctttgtttc cataaactat gcagtcataa ttgagaaaaa 900
25  gcaatagatg gggcttccct ccatttgttg gttattgtct gggttagcca ggagcagtg 960
    ggatggcaaa gtaggagaga gggccagagg aaagcccatc tccctccagc tttggggctc 1020
    ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
    aggtgaacag tcctacctgc ttgtaccat agtccctcaa taagattcag aggaagaagc 1140
    ttatgaaact gaaaatcaaa tcaaggtatt gggaagaata atttccctc gattccacag 1200
30  gagggagagc cacacaatat cattgtgtct gggctcccca aggccctgcc acctggcttt 1260
    acaaatcctc aggggttgcc tgcttggcag tcacatgctt ccctggtttt agcacacata 1320
    caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380
    ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatgggtg tcttttgcat 1440
    gcagttgggc tgacctgaca aagccccag tttcctgtgg caggttctgg gagaggatgc 1500
35  attcaagctt ctgcagccta ggggacaggg ctgcttgttc agttattact gcctcggagc 1560
    tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
    ctctcgagct attctcggt gtatgttctc tggcagagag aggcagatga acatagtttt 1680
    agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
    tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
40  ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
    ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
    gggggagtgg gaggggaagg aaagagaaca gacggcact gggatttgaa aggggaacct 1980
    ctctatctga ggagccccc ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
    tgaaaatttc cagaaatacc atttgggtgca tcccttgtt tctgtaatat taaactcagg 2100
45  tgaaattata ctctgacagt ttctctcttt ctgectctc cctctgcaga gtcaggacct 2160
    gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaa 2220
    gcctgaagtt atagagtgtt tacagcgggt gcgatatcca ggggtcatcg ccaactgggc 2280
    tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atccccactg 2340
    ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtacca 2400
50  gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
    catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
    ggggtgtcc
  
```

<210> 48
 <211> 1553
 <212> DNA
 <213> Human

<400> 48

```

60  tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
    ttcatatata tatatacata catatataaa ggaaacaatt tgcaaattta cacacctgac 120
    aaaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
    ctagccaggc ccgttttcca tccctaagta ccattctctc atttgggccc ttctaggggt 240
65  ggggccctga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
    tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360
  
```

5 ccatcaagag ggctatggga gccaaagtga caccggggat tgaggctaata tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttctctga 480
 gacggagtct cgctgtgttg cccaggctgg agtgcagtgg cacggctctcg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgctctg actttgtgat ccgcccgcct cggcctccca 720
 aagtgtggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780
 atgacaccag ttcttggtt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 10 agacaggagg gtggtggcag caaactgca gctgcttctg gatgctgctg ggggtgctctc 900
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtgg tgcacctgga tgggtggaag cagcctttgg ggcaggaaac cagctcagag 1020
 aggtaccaca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140
 ggatgagctt cactcaacgt ggagatggtg gtggactggt ccctgaaaag cgggctctgc 1200
 15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cgaggggagc aggaaggcttc tctctagctc ctttggaggc tttggctgag agaagagtga 1320
 gcaggagact ggggaatggtc caggcaggga agggagctga agtgattcgg ggctaatagcc 1380
 tcagatcgat gtatttctct ccctggtctc ccggagccct cttgtcaccg ctgctgccct 1440
 20 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500
 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtgggtccc agctactcag gaggtgagg cgggaggatt gcttgagccc aggagttaga 60
 tggtgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataacct 120
 gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcgggtta cgggaaaacc 180
 gcctgtcaga aacttggct actcctaccc cagatcagtg gacctgggaa tgagggttg 240
 tcccgggagg cttttctcca agctgttgcc accagaccog ccatgggaac cctggccaca 300
 35 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360
 ggaggggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420
 tgcgtgcctg tgtgtgtgag tgcctctccc ctgcagcgt cgggtggtatc tccctccagc 480
 cccttcgcca cttctgagc attgtctgtc cagctgagac tgcccagaga cagcagagct 540
 ccacgtgggt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600
 cagggtgctaa atgaccgac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660
 40 gtcccgtga cctgcccccg tggcgtctca cgggtgatgcc tgctcctgac attggtgttc 720
 actgtagcaa actaattctt ggatgggaat ttcatgtac atgtgtggca tgtggaaaat 780
 ttcaaataaa atggacttga tttagaaagc caaaaagctg tgtggctcct ccagcacgga 840
 tactttgacc tcttgcttac aacccttcc ttgggtccga ggctggtagc tttgttccact 900
 45 tcagatgggt gggggcgggt g

<210> 50

<211> 338

<212> DNA

<213> Human

50

<400> 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tcccttccag atattacccc atttctctac ttccattgt agccaaactt tccaaaaatt 120
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc acccctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgatac cataactaat gatccttcgt 240
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300
 gtaagaact tttttcttg aattcttgg tctcttgg

60

<210> 51

<211> 1191

<212> DNA

<213> Human

65

<400> 51

ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacaacat ccgggggatgg 60
ctgtgtgttg ctagagcaga ggctgattaa acactcagtg tgttggctct ctgtgccact 120
cctggaaaat aatgaattgg gtaaggaaaca gttaataaga aaatgtgcct tgctaactgt 180
5 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgtgccc gctgccgttc 240
aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300
tacaatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgtcctg acaagtcggg 360
aattttctcta tttctccact ggtgcaaaga gcggatttct ccctgcttct cttctgtcac 420
ccccgtcct ctcccccagg aggtcccttg atttatggta gctttggact tgcttccccg 480
tctgactgtc cttgacttct agaattggaag aagctgagct ggtgaaggga agactccagg 540
10 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600
aagacaaact aaagcaccag catttgaaga aaaagccctt gagggagaaa tggcttctag 660
atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720
accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780
aaaaagctga actgcāaatc tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840
15 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900
aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960
ctagggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020
tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagttctgt 1080
cttccaatac ctctggccat cagatgactt taaaaggtac aggagtaaaa gtttaagatg 1140
20 atgggcaaaa gtccagtgtg ttcagtaaag tgctaatac aagttggagg t

<210> 52

<211> 1200

<212> DNA

25 <213> Human

<400> 52

aacagggact ctactctat caaccccagg ctggagtcgg gtgcgcccac cctggctccc 60
30 tgcaacctcc gcctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120
actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180
cgcttctgt ccaggccggc atcatatact ttaaatacatg ccagatgac ttaataacct 240
aatacaatat atcagggttg tttaaaaata attgcttttt tattattttt gcatttttgc 300
35 accaacctta atgctatgta aatagttggt atactgttgc ttaacaacag tatgacaatt 360
ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtgggc tttttttttt 420
ttctcagtggt tttcaattcc tccctgggtg aatccatgga tgcaaaaccc acagatatga 480
agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540
atatgtagtg aaagttatgg tacagtggaa agagtagttg aaaacataaa catttggacc 600
40 tttcaagaaa ggtagcttgg tgaagttttt caccttcaaa ctatgtccca gtcagggtctc 660
tgctactaat tagctataat ctttgacaaa attacatcac ctttgagtct cagttgcctc 720
acctgtaaaa tgaaagaact ggatactctc taaggctact tccagccctg tcattctata 780
actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtc aactgaaaat 840
gattattaaa gtgggaaaaa gccaatgtct tctcttagaa agctcaacta aatttgagaa 900
45 gaataatctt ttcaattttt taagaattta aatattttta agggtttgac ctatttattt 960
agagatgggg tctcactctg tcacccagac tggagtacag tggcacaatc atagctcact 1020
gctgcctcaa attcatgggc tcaagtgate ctctgcctc tgccctcaga gtagctgcga 1080
ctatgggcat gtgccaccac gcttggttaa catttgattt gacctattta tttattgtga 1140
tttatatctt tttttttttt tctttttttt ttttttacia aatcagaaat acttattttg 1200

50 <210> 53

<211> 989

<212> DNA

<213> Human

55 <400> 53

aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtga catttatttt 60
tatgcctttc ttcttatgtg tattttcaagt ctttttcaaa acaaggcccc aggactctcc 120
60 gattcaatta gtccctgggc tggctgactg tgcaggagtc caggagacct ctacaaatgc 180
agagtgaact tttaccaaca taaaccctag atacatgcaa aaagcaggac ccttccctcca 240
ggaatgtgcc atttcagatg cacagcaccg atgcagaaaa gctggaattt tccttggaa 300
cgactgtgat agaggtgctt acatgaacat tgcactgtc tttctttttt tttgagacag 360
gtttcgttgg tgcccaggct gagtgcaatg cgtgatctca ctactgcaa ttccacctcc 420
aggttcaage attctcctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480
65 ccggctaatt ttgtattttt gtagagatgg atttctccat ttggtcaggc ggtctcgaac 540
cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600

	cgaccggcca	ctactgtctt	tctttgaccc	ttccagtttc	gaagataaag	aggaaataat	660
	ttctctgaag	tacttgataa	aattttccaaa	caaaacacat	gtccacttca	ctgataaaaa	720
	atttacggca	gtttggcacc	taagagtatg	acaacagcaa	taaaaagtaa	tttcaaagag	780
5	ttaagatttc	ttcagcaaaa	tagatgattc	acatcttcaa	gtcctttttg	aaatcagtta	840
	ttaatattat	tctttcctca	tttccatctg	aatgactgca	gcaatagttt	tttttttttt	900
	tttttttttt	ttgcgagatg	gaatctcgt	ctgtcgccca	gcgggagtg	actggcgcaa	960
	gccccgctca	ccgcaatctc	tgccacccg				
	<210>	54					
10	<211>	250					
	<212>	DNA					
	<213>	Human					
	<400>	54					
15	catttcccca	ttggctctga	tggtgaagat	ttagttaaag	aggctgtaag	tcaggttcga	60
	gcagaggcta	ctacaagaag	tagggaaatca	agtcctcac	atgggctatt	aaaactaggt	120
	agtgggtggag	tagtgaaaaa	gaaatctgag	caacttcata	acgtaactgc	ctttcaggga	180
20	aaagggcatt	cttttaggaac	tgcatctggt	aaccacacacc	ttgatccaag	agctagggaa	240
	acttcagttg						
	<210>	55					
	<211>	2270					
	<212>	DNA					
25	<213>	Human					
	<400>	55					
30	gcgcccccca	gcagcgcccc	cgccctccgc	gccttctccg	ccgggacctc	gagcgaaaga	60
	ggccccgcgc	ccgcccagcc	ctcgctcccc	tgcccaccgg	gcacaccgcg	ccgccacccc	120
	gaccccgctg	cgacggccct	gtccgctgca	caccagcttg	ttggcgctct	cgctcgccgcg	180
	ctcgccccgc	gctaactctg	cgcgccacaa	tgagctcccc	catcgccagg	gcgctcgccct	240
	tagtgcgtcac	ccttctccac	ttgaccaggc	tggecgctctc	cacctgcccc	gctgcctgcc	300
35	actgccccct	ggaggcgccc	aagtgcgcgc	cgggagtcgg	gctggctccg	gacggctgcg	360
	gctgctgtaa	ggtctgcgcc	aagcagctca	acgaggactg	cagcaaaacg	cagccctgcg	420
	accacaccaa	ggggctggaa	tgcaacttcg	gcgccaagtc	caccgctctg	aaggggatct	480
	gcagagctca	gttcagaggc	agaccctgtg	aataaactc	cagaatctac	caaaacgggg	540
	aaagtttcca	gccaactgt	aaacatcagt	gcacatgtat	tgatggcgcc	gtgggctgca	600
40	ttcctctgtg	tccccaagaa	ctatctctcc	ccaacttggg	ctgtcccaac	cctcggtcgg	660
	tcaaagttac	cgggcagtg	tgcgaggagt	gggtctgtga	cgaggatagt	atcaaggacc	720
	ccatggagga	ccaggacggc	ctccttgcca	aggagctggg	attcgatgcc	tccgaggtgg	780
	agttgacgag	aaacaatgaa	ttgattgcag	ttggaaaagg	cagctcactg	aagcggctcc	840
	ctgttttttg	aatggagcct	cgcacccctt	acaacccttt	acaaggccag	aaatgtattg	900
45	ttcaaacaac	ttcatggtcc	cagtgtctca	agacctgtgg	aactggtatc	tccacacgag	960
	ttaccaatga	caaccctgag	tgccgccttg	tgaagaaaac	ccggatttgt	gaggtgcggc	1020
	cttgtggaca	gccagtgtac	agcagcctga	aaaagggcaa	gaaatgcagc	aagaccaaga	1080
	aatcccccca	accagtcagg	tttacttacg	ctggatgttt	gagtggtgaa	aaataccggc	1140
	ccaagtactg	cggttcctgc	gtggacggcc	gatgctgcac	gccccagctg	accaggactg	1200
	tgaagatgcg	gttccgctgc	gaagatgggg	agacattttc	caagaacgtc	atgatgatcc	1260
50	agtcctgcaa	atgcaactac	aactgcccgc	atgccaatga	agcagcggtt	cccttctaca	1320
	ggctgttcaa	tgacattcac	aaatttaggg	actaaatgct	acctgggttt	ccagggcaca	1380
	cctagacaaa	caaggagaaa	gagtgtcaga	atcagaatca	tggagaaaat	gggcgggggt	1440
	ggtgtgggtg	atgggactca	ttgtagaaag	gaagccttgc	tcattcttga	ggagcattaa	1500
55	ggtatttcga	aactgccaa	ggtgctggtg	cggatggaca	ctaactgcagc	cacgatttga	1560
	gaatactttg	cttcatagta	ttggagcaca	tgttactgct	tcatttttga	gcttgtggag	1620
	ttgatgactt	tctgttttct	gtttgtaaat	tatttgctaa	gcataatttc	tctaggcttt	1680
	tttccctttg	gggttctaca	gtcgtaaaag	agataataag	attagtgtga	cagttttaaag	1740
	cttttattcg	tccttttgaca	aaagttaaag	ggagggcatt	ccatcccttc	ctgaaggggg	1800
	acactccatg	agtgtctgtg	agaggcagct	atctgcactc	taaactgcaa	acagaaatca	1860
60	ggtgttttaa	gactgaatgt	tttatttatc	aaaatgtage	ttttggggag	ggaggggaaa	1920
	tgtaatactg	gaataatttg	taaatgattt	taattttata	ttcagtgaag	agattttatt	1980
	tatggaatta	accatttaat	aaagaaatat	ttacctaata	tctgagtgtg	tgccattcgg	2040
	tattttttaga	ggtgctccaa	agtcattagg	aacaacctag	ctcacgtact	caattattca	2100
	aacaggactt	attgggatac	agcagtgaat	taagctatta	aaataagata	atgattgctt	2160
65	ttataccttc	agtagagaaa	agtcttttgc	tataaagtaa	tgtttaaaaa	acatgtattg	2220
	aacacgacat	tgtatgaagc	acaataaaga	ttctgaagct	aaaaaaaaaa		

<210> 56
 <211> 1636
 <212> DNA
 <213> Human

5

<400> 56

```

10  cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaagggg 60
    agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120
    cagtttgatt ggaagtccag ctgtgaaacc tggagcgtcg ccttctcccc agatggctcc 180
    tggtttgctt ggtctcaagg acactgcatc gtcaaactga tccccgggcc gttggaggag 240
    cagttcatcc ctaaaaggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300
    cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
15  agcccggtggc cttccccacc cagcaggaag ctctgggcac gccaccaccc ccaagtggcc 420
    gatgtctctt gcctggttct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480
    gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
    agcttcacac ccagtggcag tttgattttg gtctccgcgt cacgggataa gactcttcgc 600
    atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcggggcca cctgcagtgg 660
20  gtttactgct gttccatctc cccagactgc agcatgctgt gctctgcagc tggagagaag 720
    tcggtctttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
    agcagtgttg tctcttgtag cttctcccc cactctgccc tgcttgtcac ggcttcttac 840
    gataccaatg tgattatgtg ggacccttac accggcgaaa ggctgaggtc actccaccac 900
    acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
25  tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
    tgggcccttg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgctgc 1080
    acatttttcc cacatgggtg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
    tggacagctc ctagggctct gtccctcact aagcacttat gccggaaagc ccttcgaagt 1200
    ttcttaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcctc 1260
30  acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatcgt 1320
    cctgtcaaag ggagttgctg gaataatggg ccaaacatct ggtcttgcat tgaatatgca 1380
    tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
    tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500
    aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
35  aagatggtga aggggtggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
    gaccctgtgc tgcgtt
  
```

<210> 57
 <211> 460
 <212> DNA
 <213> Human

40

<400> 57

```

45  ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcataatgt 60
    gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
    tggaaatgagc taagcagcc gcctgggggtg ggaggccgag cccatttgta tgcagcaggg 180
    ggacaggagcc cagcaaggga gcctccattc ccaggactct ggagggagct gagaccatcc 240
    atgcccgcag agccctccct cactctccat cctgtccagc cctaattgtg caggtgggga 300
50  aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aaccaacca 360
    gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420
    ccgagctcga attcgtaatc atggtcatag ctgtttcctg
  
```

<210> 58
 <211> 1049
 <212> DNA
 <213> Human

55

<400> 58

```

60  atctgatcaa gaatacctgc cctggctcact ctgcggatgt ttctgtccac ttgttcacat 60
    tgaggaccaa gatatacctt tttacagagg cacttgctcg gtctaacaca gacacctcca 120
    tgacgacatg ctgggtcaca ttttgagtt ctgcagaagt cccccctcca gcctggacta 180
    cagcagcact ttcccggtgg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240
65  gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
    ggatctacaa tttttagtag ttttccattg tgagtctggg tcatactttt actgcttgat 360
  
```

5 aaaatgtaaa cttcacctag ttcatottt ccaaatecca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggacttttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatctttctg actggcagcc cgggtataca aatccacca ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660
 attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctggtt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
 10 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 aacccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaacccgt cagggccaaa gagcagttgc cctccagat gctttctgtg gagttctgca 1020
 acttcaagaa agactctggc tgttctcaa

15 <210> 59
 <211> 747
 <212> DNA
 <213> Human

20 <400> 59

25 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaataata atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcatataaa 180
 gttgttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctgctctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaaa agattccagt gccctgaag aggctccctt cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctoggtgatg gctgtagatg ctaacactgg 540
 30 ccaattcaat gccacaccta ctggttacct tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660
 gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcaattta gtagtaatag cggccgc

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.